JYNNEOS Vaccine Coverage by Jurisdiction

As of January 10, 2024, this data will no longer be updated.

The figure on this page shows vaccine coverage by jurisdiction for the estimated population at risk for mpox in people who have had at least one dose and who are fully vaccinated. CDC estimates show that without continued efforts to vaccinate people with the highest risk of mpox exposure, including newly sexually active gay, bisexual, and other men who have sex with men (MSM), a resurgence of mpox will become more likely over time.


JYNNEOS vaccine (the vaccine used in the current mpox outbreak) is effective at preventing mpox among people at risk of mpox. According to MMWR, JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox — United States, May 22, 2022–January 31, 2023, although approximately 1.2 million vaccine doses have been administered, only 23% of the population at risk has been fully vaccinated nationally. Vaccine coverage varies widely between jurisdictions. Reasons for coverage variability could include lower vaccine accessibility and awareness, fewer vaccine providers, lower vaccine confidence and demand, and concern about stigma.

To prevent new cases of mpox and future outbreaks, public health agencies and their partners are strongly encouraged to continue to improve vaccine equity and vaccine coverage among those at risk for mpox and increase the number of people fully vaccinated especially among those overly represented communities of Black and Hispanic or Latino men.

Data will be updated once per month after they are reviewed and verified. Updates may be delayed due to delays in reporting (generally due to holidays).

Data Used for Mpox Vaccine Coverage Figures

Defining Vaccine Coverage and People at Increased Risk

Mpox vaccine coverage is the estimated proportion of people who have received JYNNEOS vaccination divided by the population recommended to receive the vaccine. This metric helps assess how well the population at risk is protected from mpox. CDC currently recommends mpox vaccination for populations at increased risk of mpox exposure, including gay, bisexual and other men who have sex with men (MSM) with multiple recent sexual partners, MSM with HIV, those with a known or suspected exposure to mpox, women who have a male sexual partner that meets the above criteria, and laboratory and health care workers working with orthopoxviruses. CDC has updated recommendations for mpox vaccination. The number of people eligible for vaccination is estimated from other CDC data sources.

Defining the Numerator and Denominator

The denominator (MSM++) is the population recommended to receive the vaccine, which is estimated using 2021 data for MSM with HIV pre-exposure prophylaxis (PrEP) indications and 2020 data for HIV prevalence among MSM from CDC AtlasPlus. The numerator for the vaccination coverage calculation is the number of people vaccinated. Fully vaccinated is defined as people 13 years of age and older who have received two JYNNEOS vaccine doses on different days, regardless of the time interval, and who have been vaccinated with their second dose for at least 14 days. This mpox vaccine administration data are collected by jurisdictional Immunization Information Systems (IIS) and reported to the CDC Immunization Data Lake.

The denominator is the population recommended to receive the vaccine, which is estimated using 2021 data for MSM with HIV pre-exposure prophylaxis (PrEP) indications and 2020 data for HIV prevalence among MSM from CDC AtlasPlus. These estimates are increased by 25% to account for additional vaccine eligible people not captured by these data sources, such as MSM who are at increased risk for mpox but do not have indications for PrEP, cis-female or transgender partners of MSM, close contacts of persons with known or suspected mpox, and persons at risk for occupational exposure to orthopoxviruses.


  • For the most complete and up-to-date data for any particular state or city, visit the relevant health department website. The data that CDC has used to estimate denominators are from 2020 and 2021, the most recent publicly available data on a national scale. Health departments may have more recent estimates of populations at risk for mpox for their jurisdictions; this is one reason that local estimates may differ from the CDC estimates. Coverage estimates include assumptions based on national data applied to subnational jurisdictions, and coverage estimates for some jurisdictions might be biased.
  • In cases where a person’s place of residence was not provided to the vaccination site, the site’s location might have been erroneously used for place of residence.
Numerator/denominator data for each jurisdiction